Novavax, Inc. (NVAX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of May 23, 2025

$7.25

P/E Ratio

2.73

Market Cap

$1.17B

Description
Add to research
View more

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Metrics
Add to research
View more

Overview

  • HQGaithersburg, MD
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerNVAX
  • Price$7.25-0.55%

Trading Information

  • Market cap$1.17B
  • Float91.13%
  • Average Daily Volume (1m)13,712,931
  • Average Daily Volume (3m)8,236,800
  • EPS$3.05

Company

  • Revenue$1.25B
  • Rev growth (1yr)610.30%
  • Net income$518.65M
  • Gross margin97.93%
  • EBITDA margin78.66%
  • EBITDA$524.36M
  • EV$625.08M
  • EV/Revenue0.50
  • P/E2.73
  • P/S1.03
  • P/BN/A
  • Debt/EquityN/A
Documents
Add to research
View more
SEC Filings
8-K (2025-05-19)
8-K (2025-05-08)
8-K (2025-05-05)
8-K (2025-04-29)
8-K (2025-04-23)
8-K (2025-04-02)
8-K (2025-03-11)
8-K (2025-03-04)
8-K (2025-02-27)
8-K (2025-01-13)
8-K (2024-12-30)
8-K (2024-12-18)
8-K (2024-12-04)
8-K (2024-11-20)
8-K (2024-11-12)
8-K (2024-11-05)
8-K (2024-10-16)
8-K (2024-10-03)
8-K (2024-08-08)
8-K (2024-06-14)
8-K (2024-06-06)
8-K (2024-05-23)
8-K (2024-05-13)
8-K (2024-05-10)
8-K (2024-04-26)
8-K (2024-03-26)
8-K (2024-02-28)
8-K (2024-02-22)
8-K (2024-01-31)
8-K (2024-01-08)
8-K (2023-12-05)
8-K (2023-11-17)
8-K (2023-11-09)
8-K (2023-10-03)
8-K (2023-08-08)
8-K (2023-07-11)
8-K (2023-07-07)
8-K (2023-05-09)
8-K (2023-04-04)
8-K (2023-03-22)
8-K (2023-03-14)
8-K (2023-03-02)
8-K (2023-02-28)
8-K (2023-01-09)
10-Q (2025-05-08)
10-Q (2024-11-12)
10-Q (2024-08-08)
10-Q (2024-05-10)
10-Q (2023-11-09)
10-Q (2023-08-08)
10-Q (2023-05-09)
10-K (2025-02-27)
10-K (2024-02-28)
10-K (2023-02-28)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Novavax, Inc. Q3 ($6.83, +0.03) (2023-11-09T18:42:09Z)
Novavax's updated protein-based COVID-19 vaccine now an option for all 194 member states of the WHO ($5.46, 0.00) (2023-11-28T11:03:23Z)
Novavax's COVID-19 vaccine Nuvaxovid receives full approval in Singapore ($6.45, 0.00) (2023-10-18T12:04:34Z)
Novavax, Inc. reports Q3 GAAP EPS ($1.26) vs year-ago ($2.15) - 10-Q ($6.80, 0.00) (2023-11-09T12:37:11Z)
Novavax, Inc. issues press release on Q3 results; reports Q3 GAAP EPS ($1.26) vs FactSet ($1.80) [6 est, ($2.71)-0.28]; prepares to initiate cost reduction program ($6.80, 0.00) (2023-11-09T14:07:35Z)
Novavax receives full marketing authorization for prototype COVID-19 vaccine Nuvaxovid ▼ in United Kingdom ($6.45, 0.00) (2023-10-18T12:08:16Z)
Novavax finalizes agreements with pharmacy retailers and GPOs to provide the company's Covid-19 vaccine ($7.45, 0.00) (2023-10-13T13:33:32Z)
Novavax comments on WHO's recommendation of R21/Matrix-M malaria vaccine ($7.17, -0.07) (2023-10-02T17:07:59Z)
Novavax appoints John Trizzino to newly created role of President and COO ($5.83, 0.00) (2023-11-17T12:17:26Z)
Follow-up: FDA amends EUA for Novavax's COVID-19 vaccine to include 2023-2024 formula ($6.84, -0.25) (2023-10-03T18:44:13Z)
CORRECTION: Novavax, Inc. guides FY revenue $900M-$1.10B vs prior guidance $1.30-1.50B and FactSet $1.37B [6 est, $1.35-1.40B] ($6.80, 0.00) (2023-11-09T14:11:02Z)
Earnings Calls
Earnings Report 2025Q1
Earnings Report 2024Q4
Earnings Report 2024Q3
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-09)
Earnings Report (2023-08-08)
Factset
Factset Business Description
Wikipedia
Novavax,_Inc.